GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acura Pharmaceuticals Inc (OTCPK:ACUR) » Definitions » Price-to-Owner-Earnings

Acura Pharmaceuticals (Acura Pharmaceuticals) Price-to-Owner-Earnings : (As of May. 16, 2024)


View and export this data going back to 1992. Start your Free Trial

What is Acura Pharmaceuticals Price-to-Owner-Earnings?

As of today (2024-05-16), Acura Pharmaceuticals's share price is $0.0041. Acura Pharmaceuticals does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Acura Pharmaceuticals's Price-to-Owner-Earnings or its related term are showing as below:


ACUR's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 28.44
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-16), Acura Pharmaceuticals's share price is $0.0041. Acura Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2021 was $-0.02. Therefore, Acura Pharmaceuticals's PE Ratio for today is At Loss.

As of today (2024-05-16), Acura Pharmaceuticals's share price is $0.0041. Acura Pharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.03. Therefore, Acura Pharmaceuticals's PE Ratio without NRI for today is At Loss.


Acura Pharmaceuticals Price-to-Owner-Earnings Historical Data

The historical data trend for Acura Pharmaceuticals's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acura Pharmaceuticals Price-to-Owner-Earnings Chart

Acura Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Acura Pharmaceuticals Quarterly Data
Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Acura Pharmaceuticals's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Acura Pharmaceuticals's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acura Pharmaceuticals's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Acura Pharmaceuticals's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Acura Pharmaceuticals's Price-to-Owner-Earnings falls into.



Acura Pharmaceuticals Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Acura Pharmaceuticals's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.0041/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Acura Pharmaceuticals  (OTCPK:ACUR) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Acura Pharmaceuticals Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Acura Pharmaceuticals's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Acura Pharmaceuticals (Acura Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
616 N. North Court, Suite 120, Palatine, IL, USA, 60067
Acura Pharmaceuticals Inc is a specialty pharmaceutical company based in the United States. It is engaged in the research, development, and commercialization of technologies and products intended to address medication abuse and misuse. The company's product portfolio includes Limitx, Oxaydo, and Nexafed.
Executives
Bruce F Wesson director 1827 PACIFIC ST BROOKLYN NY 11233
William G Skelly director C/O ACURA PHARMACEUTICALS, INC. 616 N. NORTH COURT, SUITE 120 PALATINE IL 60067
George K Ross director 1350 TREAT BLVD SUITE 250 WALNUT CREEK CA 94596
James F Emigh officer: VP, Corporate Development
Immanuel Thangaraj director 10001 WOODLOCH FOREST DRIVE SUITE 175 THE WOODLANDS TX 77380
Robert A Seiser officer: VP, Treasurer & Controller C/O ACURA PHARMACEUTICALS, INC. 616 N. NORTH COURT SUITE 120 PALATINE IL 60067
Robert B Jones officer: President & CEO C/O ACURA PHARMACEUTICALS, INC. 616 N NORTH COURT PALATINE IL 60067
Albert W Brzeczko officer: VP Pharmaceutical Sciences APT C/O ACURA PHARMACEUTICALS, INC. 660 N. NORTH COURT PALATINE IL 60067
Peter A Clemens officer: Senior VP & CFO C/O HALSEY DRUG CO INC 1827 PACIFIC STREET BROOKLYN NY 11233
Abuse Deterrent Pharma, Llc 10 percent owner 333 EAST MAIN STREET SUITE 200 LOUISVILLE KY 40202
Claudius Llc 10 percent owner C/O GALEN ASSOCIATES 610 FIFTH AVENUE 5TH FLOOR NEW YORK NY 10020
John Schutte 10 percent owner 9707 SHELBYVILLE ROAD, LOUISVILLE KY 40233
Galen Partners Iii L P 10 percent owner 610 FIFTH AVE 5TH FL NEW YORK NY 10020
Galen Management, Llc 10 percent owner 680 WASHINGTON BLVD, STAMFORD CT 06901
Galen Employee Fund Iii Lp 10 percent owner 610 FIFTH AVENUE 5TH FLOOR NEW YORK NY 10020

Acura Pharmaceuticals (Acura Pharmaceuticals) Headlines

From GuruFocus

Acura Pharmaceuticals and AD Pharma Amend License to LIMITx� LTX-03

By GuruFocusNews GuruFocusNews 03-01-2022

Acura Pharmaceuticals Licenses LIMITx™ LTX-03

By Marketwired Marketwired 07-03-2019

What to Watch for: November 3-7

By TipRanks TipRanks 11-04-2014

Acura Pharmaceuticals Announces Conversion of Debt

By Marketwired Marketwired 06-14-2021